Millennium/Sanofi Discontinue Phase II CCR1 Inhibitor For Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Candidate demonstrated safety but did not reach prespecified endpoint, Millennium CEO Dunsire says.